Description
Depression Screening Market Analysis
Market Overview
According to the report, the global Depression Screening Market is projected to register a notable Compound Annual Growth Rate (CAGR) of 5.89% during the review period. There are a few elements driving the development of the market are expanding the commonness of mental problems and ascending in the reception of new treatments and medicines.
The rising pervasiveness of mental problems across the globe is among the critical elements energizing the development of the depression screening market. As per the World Wellbeing Association (WHO), there has been a 13% expansion in emotional well-being conditions and other burdensome issues somewhat recently. Essentially, as per the US Division of Wellbeing and Human Administration (HHS), in 2020, it is assessed that 4.1 million young people ages 12 and 17 had a significant burdensome episode, and 2.9 million had a significant burdensome episode with serious hindrance. Hence, the rising number of patients with related messes is adding to the development in the worldwide market.
Market Segmentation
Major depressive disorder, anxiety distress, bipolar disorder, psychotic disorders, and other conditions are included in the indication-based segmentation of the depression screening market.
The diagnosis, psychological tests, blood tests, pharmacogenomic testing, and other factors have all been considered when segmenting the depression screening market.
The global depression screening market has been divided into three categories depending on end users: home-based, research and academic institutions, and hospitals and clinics.
Regional Analysis
North America depression screening market represented the biggest market share in 2021, because of variables credited to its enormous offer incorporating created healthcare foundation, expanding mechanical progression about emotional wellness, and the presence of countless
Market Players
Europe depression screening market represents the second-biggest market share attributable to the developing pervasiveness of various kinds of burdensome problems among people, and the rising consciousness of treating these burdensome illnesses are the central point that are driving the market development in Europe.
For example, as per the examination distributed by the Emergency clinic del Blemish Clinical Exploration Organization (IMIM) in July 2021, around 6.4% of the European populace experiences depression. Moreover, the German depression screening market held the biggest market share in 2021 and is the quickest developing during the gauge time frame.
The Asia-Pacific depression screening market is supposed to develop at a huge offer from 2022 to 2030. The region’s rising extra cash of people, expanding assets in research exercises, and rising commonness of mental problems is the central point that is driving the market development in Asia-Pacific. Also, Japan’s depression screening market held the biggest market share, and India is the quickest developing market during the gauge time frame.
Major Players
Key Companies in the Depression Screening Market include Medtronic (Ireland), Pearson (UK), PAR, Inc. (US), SIGMA Assessment Systems Inc. (US), Siemens Healthineers (Germany), Danaher Corporation (US), National Psychological Corporation (India), Bruker (US), Multi-Health Systems Inc. (US), Nedley Health (US), and Others.
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
1.1 OVERVIEW
1.1.1 MARKET SYNOPSIS
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 LIST OF ASSUMPTIONS
3 RESEARCH METHODOLOGY
3.1 OVERVIEW
3.2 DATA MINING
3.3 SECONDARY RESEARCH
3.4 PRIMARY RESEARCH
3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 INCREASING PREVALENCE OF MENTAL DISORDERS
4.2.2 RISE IN ADOPTION OF NEW THERAPIES AND TREATMENTS
4.2.3 RISING NUMBER OF STRATEGIC INITIATIVES
4.3 RESTRAINTS
4.3.1 LACK OF AWARENESS AMONG PEOPLE
4.3.2 DEARTH OF QUALIFIED MENTAL HEALTH PROFESSIONALS
4.4 OPPORTUNITIES
4.4.1 INCREASING TECHNOLOGICAL ADVANCEMENT IN REGARD TO MENTAL HEALTH
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 PRODUCT DEVELOPMENT & BUSINESS ACQUISITION (PDBA)
5.1.2 SALES AND MARKETING
5.1.3 CONTRACT MANAGEMENT
5.1.4 CUSTOMER SERVICE & SUPPORT
5.2 PORTER’S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE GLOBAL DEPRESSION SCREENING MARKET
5.3.1 IMPACT ON MARKET GROWTH
5.3.2 IMPACT ON VALUE CHAIN
5.3.3 IMPACT ON END USERS
6 GLOBAL DEPRESSION SCREENING MARKET, BY INDICATON
6.1 OVERVIEW
6.2 MAJOR DEPRESSIVE DISORDER
6.3 ANXIETY DISTRESS
6.4 BIPOLAR DISORDER
6.5 PSYCHOTIC DISORDERS
6.6 OTHERS
7 GLOBAL DEPRESION SCREENING MARKET, BY DIAGNOSIS
7.1 OVERVIEW
7.2 PSYCHOLOGICAL TESTS
7.3 BLOOD TESTS
7.4 PHARMACOGENOMIC TESTING
7.5 OTHERS
8 GLOBAL DEPRESSION SCREENING MARKET, BY END USER
8.1 OVERVIEW
8.2 HOSPITALS AND CLINICS
8.3 HOME-BASED
8.4 RESEARCH AND ACADEMIC INSTITUTES
9 GLOBAL DEPRESSION SCREENING MARKET, BY REGION
9.1 OVERVIEW
9.2 NORTH AMERICA
9.2.1 US
9.2.2 CANADA
9.3 EUROPE
9.3.1 GERMANY
9.3.2 UK
9.3.3 FRANCE
9.3.4 ITALY
9.3.5 SPAIN
9.3.6 REST OF EUROPE
9.4 ASIA-PACIFIC
9.4.1 JAPAN
9.4.2 CHINA
9.4.3 INDIA
9.4.4 SOUTH KOREA
9.4.5 AUSTRALIA
9.4.6 REST OF ASIA-PACIFIC
9.5 REST OF THE WORLD
9.5.1 MIDDLE EAST
9.5.2 AFRICA
9.5.3 LATIN AMERICA
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 COMPETITIVE BENCHMARKING
10.3 MAJOR GROWTH STRATEGY IN THE GLOBAL DEPRESSION SCREENING MARKET
10.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL DEPRESSION SCREENING MARKET
10.5 KEY DEVELOPMENT ANALYSIS
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
10.6.1 PRODUCT LAUNCH/ PRODUCT APPROVAL
10.6.2 PARTNERSHIP/AGREEMENT
10.6.3 MERGER /ACQUISTION
10.7 FINANCIAL MATRIX
10.7.1 SALES (USD MILLION), 2021
10.7.2 R&D EXPENDITURE (USD MILLION), 2021
11 COMPANY PROFILES
11.1 NATIONAL PSYCHOLOGICAL CORPORATION
11.1.1 COMPANY OVERVIEW
11.1.2 FINANCIAL OVERVIEW
11.1.3 PRODUCTS OFFERED
11.1.4 KEY DEVELOPMENTS
11.1.5 KEY STRATEGIES
11.2 BRUKER
11.2.1 COMPANY OVERVIEW
11.2.2 FINANCIAL OVERVIEW
11.2.3 PRODUCTS OFFERED
11.2.4 KEY DEVELOPMENTS
11.2.5 SWOT ANALYSIS
11.2.6 KEY STRATEGIES
11.3 MEDTRONIC
11.3.1 COMPANY OVERVIEWS
11.3.2 FINANCIAL OVERVIEW
11.3.3 PRODUCTS OFFERED
11.3.4 KEY DEVELOPMENTS
11.3.5 SWOT ANALYSIS
11.3.6 KEY STRATEGIES
11.4 MULTI-HEALTH SYSTEMS INC.
11.4.1 COMPANY OVERVIEW
11.4.2 FINANCIAL OVERVIEW
11.4.3 PRODUCTS OFFERED
11.4.4 KEY DEVELOPMENTS
11.4.5 KEY STRATEGIES
11.5 NEDLEY HEALTH
11.5.1 COMPANY OVERVIEW
11.5.2 FINANCIAL OVERVIEW
11.5.3 PRODUCTS OFFERED
11.5.4 KEY DEVELOPMENTS
11.5.5 KEY STRATEGIES
11.6 DANAHER CORPORATION
11.6.1 COMPANY OVERVIEW
11.6.2 FINANCIAL OVERVIEW
11.6.3 PRODUCTS OFFERED
11.6.4 KEY DEVELOPMENTS
11.6.5 SWOT ANALYSIS
11.6.6 KEY STRATEGIES
11.7 PEARSON
11.7.1 COMPANY OVERVIEW
11.7.2 FINANCIAL OVERVIEW
11.7.3 PRODUCTS/SERVICES OFFERED
11.7.4 KEY DEVELOPMENTS
11.7.5 SWOT ANALYSIS
11.7.6 KEY STRATEGIES
11.8 SIGMA ASSESSMENT SYSTEMS INC.
11.8.1 COMPANY OVERVIEW
11.8.2 FINANCIAL OVERVIEW
11.8.3 PRODUCTS OFFERED
11.8.4 KEY DEVELOPMENTS
11.8.5 KEY STRATEGIES
11.9 SIEMENS
11.9.1 COMPANY OVERVIEW
11.9.2 FINANCIAL OVERVIEW
11.9.3 PRODUCTS OFFERED
11.9.4 KEY DEVELOPMENTS
11.9.5 SWOT ANALYSIS
11.9.6 KEY STRATEGIES
11.10 PAR, INC.
11.10.1 COMPANY OVERVIEW
11.10.2 FINANCIAL OVERVIEW
11.10.3 PRODUCTS OFFERED
11.10.4 KEY DEVELOPMENTS
11.10.5 KEY STRATEGIES
11.11 MYRIAD GENETICS, INC.
11.11.1 COMPANY OVERVIEW
11.11.2 FINANCIAL OVERVIEW
11.11.3 PRODUCTS OFFERED
11.11.4 KEY DEVELOPMENTS
11.11.5 KEY STRATEGIES
12 APPENDIX
12.1 REFERENCES
12.2 RELATED REPORTS
